March 13, 2026 / Last updated : March 13, 2026 Michele Webb artificial intelligence Cancer Registry’s Competitive Advantage The Cancer Registry competitive advantage is staying committed to the process until the data serves clinicians and patients.
March 13, 2026 / Last updated : March 13, 2026 Michele Webb Cancer Registrar Cancer Registry Defines Next Steps Cancer registry data is the bridge between clinical reality and operational decisions, because it does not just record events, it makes them actionable. “What happened” becomes “what do we do next” when registrars deliver standardized, decision-grade data fast enough to influence pathways, clinical decisions, and service-line strategy. Automation and workflow optimization is the amplifier: it […]
March 13, 2026 / Last updated : March 13, 2026 Michele Webb Cancer Registrar Bridge Between Clinical and Operational Reality Cancer registry data does not just describe care, it makes care measurable, comparable, and accountable across silos, sites, and time. When we translate clinical reality into operational truth, we turn anecdotes into evidence and dashboards into decisions that actually change outcomes. The question is not whether we have data, it’s whether we are using it […]
March 13, 2026 / Last updated : March 13, 2026 Michele Webb Cancer Registrar Measureable Oncology Insights Measurement is not a metric—it is a system for comparability. Cancer registry data turns fragmented records into accountable oncology performance.
March 13, 2026 / Last updated : March 13, 2026 Michele Webb Cancer Registrar Decision-Ready Data: Where Is It? Assets like the cancer registry are, by design, used to amplify and strengthen the oncology service line. Each case in the Registry contains decision-ready data that is carefully coded and validated by an ODS who received specialized training. The equation looks like this: ODS + Workflow Optimization + Validated Data = Clinical and Operational Decision […]
March 13, 2026 / Last updated : March 13, 2026 Michele Webb artificial intelligence It’s a Privilege It has been my honor and privilege to serve as a cancer registrar, speaker, and author for the past 20+ years! Registrars are a unique healthcare professional, highly trained in anatomy and physiology, cancer disease process, and the healthcare delivery process. Not only has clinical and scientific medicine changed dramatically since I first started, but […]
February 15, 2026 / Last updated : February 15, 2026 Michele Webb artificial intelligence What It Means When a Cancer Registrar Says, “There Is No Room for AI in the Cancer Registry” Why do cancer registrars say, “There is no room for AI in the cancer registry?” As a cancer registrar who advocates for thoughtful AI automation, I hear this phrase often. In most cases, it is not opposition to innovation. It is a signal of perceived risk without control. AI has been part of registry work […]
February 15, 2026 / Last updated : February 15, 2026 Michele Webb artificial intelligence Why Saying AI Solutions Can “Do More With Less” Triggers Fear “Do more with less.” Four words that can instantly trigger alarm for cancer registrars. For many, the phrase activates a stress response rooted in familiar pressures: unrealistic expectations, shrinking timelines, or a perceived loss of control. When a team is already operating at maximum capacity, it can widen the gap between what leadership expects and […]
February 15, 2026 / Last updated : February 15, 2026 Michele Webb Cancer Registry The ODS’ AI Strategy As oncology data specialists (ODS’ or cancer registrars), being a good steward of technology and resources means the team (cancer registrars, administrators, IT, and vendors) develop a strong strategy, define the problem(s), set expectations, and measures results.
October 21, 2025 / Last updated : November 18, 2025 Michele Webb Cancer Registry Think Beyond the Obvious The real challenge is finding what was missed. In an earlier post we explored how clinically diagnosed lung cancers often escape case finding. But the problem runs deeper: incomplete casefinding does not just miss patients—it reshapes the national picture of cancer itself. When symptom-based encounters, LDCT screening and imaging reports with ambiguous terminology, or clinical […]